GeoVax Labs Inc (GOVX)
Official siteHEALTHCARE • BIOTECHNOLOGY • NASDAQ
Market Cap: $928,290
Last updated: Nov 17, 2026 at 4:29 PM ET
GeoVax Labs Inc (GOVX) Stock Chart
GeoVax Labs (GOVX) has a latest price of $2.01 on Nov 17, 2026, 99.3% below its 52-week high of $270.66. Its price fell 99.3% over the past 12 months. The month-end price fell 100.0% over the 10 years through Oct 2026, a compound annual decline of 88.7%.
Price Chart
From Oct 2016 to Oct 2026, its highest month-end close was $12,439,823,253.84 in Oct 2016 and its lowest $4.04 in Oct 2026, adjusted for splits.
Month-end closes, adjusted for splits. Dividends are not included.
Chart GOVX with Advanced Charting
Daily candlesticks, valuation multiples, side-by-side comparisons and drawings for GOVX.
Free with a GNG account. No credit card.
Price Performance
Over the past 3 months the price fell 85.9%, and over 6 months it fell 95.8%. The month-end price fell 99.9% over the 3 years through Oct 2026, a compound annual decline of 90.3%.
| Period | Change |
|---|---|
| 1 month | -63.2% |
| 3 months | -85.9% |
| 6 months | -95.8% |
| 12 months | -99.3% |
| 12 months, with dividends | -99.3% |
| Period | Change | Per year |
|---|---|---|
| 3 years | -99.9% | -90.3% |
| 5 years | -100.0% | -83.9% |
| 10 years | -100.0% | -88.7% |
Price by Year
Its best calendar year was 2021, when the price rose 7.1%, and its weakest was 2019, when it fell 100.0%.
| Year | Close | Change |
|---|---|---|
| 2026 through Oct 2026 | $4.04 | -96.1% |
| 2025 | $102.52 | -93.1% |
| 2024 | $1,480.82 | -54.4% |
| 2023 | $3,244.78 | -42.7% |
| 2022 | $5,664.43 | -82.6% |
| 2021 | $32,537.69 | +7.1% |
| 2020 | $30,380.49 | -71.8% |
| 2019 | $107,859.74 | -100.0% |
| 2018 | $4,314,389,567.81 | -52.0% |
| 2017 | $8,988,311,599.60 | -19.4% |
Trading Range
The price is 68.2% below its 50-day average of $6.32 and 92.3% below its 200-day average of $26.20.
| Measure | Value | Price vs |
|---|---|---|
| Latest price (Nov 17, 2026) | $2.01 | |
| 52-week high | $270.66 | -99.3% |
| 52-week low | $1.50 | +33.6% |
| 50-day average | $6.32 | -68.2% |
| 200-day average | $26.20 | -92.3% |
Price Risk
Over 3 years, its largest fall from a peak was 100.0%.
| Measure | Value |
|---|---|
| 1-year beta | 1.25 |
| Largest fall, 1 year | -99.3% |
| Largest fall, 3 years | -100.0% |
Advanced Charting Features
Advanced Charting is free with a GNG account, and signed-in members get it in place of the price chart above.
- Valuation multiples. Daily P/E, price to sales, cash flow and book value, PEG and PEGY, drawn behind the price wherever the company's data supports them.
- Price charts and drawings. Candlestick, OHLC, line and area charts with volume and earnings, dividend and split markers, plus trend lines, levels and notes kept in your account.
- Side-by-side compare. Two stocks next to each other on one metric and time span, each chart with its own price scale.
- Projections and saved views. Pick a start and an end point to see the price return, dividends and total return between them, and save views to open later.
Frequently Asked Questions About GOVX
What is GOVX's 1-year price change?
GeoVax Labs's price fell 99.3% over the past 12 months. With dividends included, the 12-month total return was -99.3%.
What is GOVX's 5-year price change?
GeoVax Labs's month-end price fell 100.0% over the 5 years through Oct 2026, a compound annual decline of 83.9%. These figures leave out dividends.
What is GOVX's 52-week high and low?
GeoVax Labs's 52-week high is $270.66 and its 52-week low is $1.50. Its latest price of $2.01 on Nov 17, 2026 is 99.3% below the high.
What is GOVX's beta?
GeoVax Labs's 1-year beta against the S&P 500 is 1.25, so its price has moved more than the market over the past year. Its largest fall from a peak over the past year was 99.3%.
Is the GOVX chart free?
Yes. Advanced Charting for GOVX is free with a GNG account, and no credit card is needed. It adds daily candlestick and line charts with volume, valuation multiples, side-by-side comparisons, drawings and saved views.
GOVX pages: Overview, Charting, Earnings, Forecast, Financials, Statistics, Competitors